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Parathyroid hormone-related protein (PTH-rP), a secreted protein produced by prostate carcinoma and other epithelial cancers, is
considered a key agent for the development of bone metastases. We investigated the construct GC90/IRIV, composed of
immunopotentiating reconstituted influenza virosomes (IRIV) containing PTH-rP gene plasmids (GC90), as a potential tool for human
anticancer immunotherapy into humanised mice transgenic for HLA-A(*)02.01, the human-b2 microglobulin, and the human CD8a
molecule. Intranasal administration of GC90/IRIV resulted in the induction of a PTH-rP-specific multiepitope cytotoxic T-cell (CTL)
response. Cytotoxic T cells derived from vaccinated mice were capable of lysing in vitro syngenic murine PTH-rP transfectants and
human HLA-A(*)02.01
þ/PTH-rP
þ prostate carcinoma LNCaP cells as well. The immune response capacity and the absence of any
sign of toxicity and/or autoimmunity in vivo suggest the GC90/IRIV vaccine as a valid tool for active specific immunotherapy of human
cancers and metastases overexpressing PTH-rP.
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Prostate cancer is the second leading cause of cancer-related death
in males in Europe and the US (Zaccagnini, 1999) and the
development of hormone-resistant metastatic bone metastases is
one of the major causes of morbidity and mortality related to this
malignancy. Parathyroid hormone-related protein (PTH-rP) is an
attractive candidate as a target antigen in the protocol of active
specific immunotherapy of prostate carcinoma and epithelial
malignancy bone metastases. It was originally described as the
factor responsible for humoral hypercalcaemia of malignancy
(HHM) (Suva et al, 1987; Francini et al, 1993). It is expressed in
90% of prostate and (spindle-cell) lung cell carcinomas and 95% of
bone metastases of epithelial cancers, and is produced in small
amounts in normal adult tissues (Iguchi et al, 1996). It is also
responsible for tumour cell growth and survival in the bone tissue,
as long as it stimulates osteoclast activity and production of
growth factors, cytokines, and TGF-a, which in turn promote
tumour cell growth and make the bone a feasible microenviron-
ment for tumour growth (Guise, 1997).
Previous studies of our group demonstrated that a specific
cytotoxic T-cell (CTL) response ex vivo could be elicited from
healthy donor PBMC as well as tumour-infiltrating lymphocytes
(TILs) derived from prostate carcinoma bone metastases stimu-
lated in vitro with autologous dendritic cells (DC) pulsed with
peptide epitopes derived from PTH-rP-expressing HLA-A(*)02.01-
binding amino-acid consensus motifs (Correale et al, 2001a;
Francini et al, 2002). Although some of them expressed
nonconventional HLA-A(*)02.01-binding motifs, these peptides
were all able to induce a PTH-rP-specific CTL response in human
PBMCs in vitro and in a former HLA-A(*)02.01 transgenic mice
model in vivo.
Different approaches of active immunisation are currently
explored for the treatment of human cancer (Fynan et al, 1993;
Paglia et al, 1996; Hwu, 1997) and the role for the DNA-based
anticancer vaccine is rapidly rising. In this context, we investigated
the capacity of influenza virosomes including PTH-rP gene
plasmids to stimulate a specific antitumour CTL response as a
delivery system for PTH-rP gene expression. Immunopotentiating
reconstituted influenza virosomes (IRIV) are influenza virosomes
carrying on the surface the two envelope glycoproteins of the
influenza virus, one of which is the influenza haemagglutinin (HA)
that facilitates the targeting of plasmid DNA to APCs, improving
the transfection efficiency and reducing the rate of DNA
degradation by extracellular nucleases (Meyer et al, 1995; Dzau
et al, 1996). We previously showed the GC90/IRIV capacity to elicit
a CTL response in vivo into BALB/c mice and in vitro in human
PBMC stimulated with IL-2 and autologous GC90/IRIV-infected
DC (Correale et al, 2001a).
The aim of this study is to investigate whether GC90/IRIV is able
to elicit a CTL response of antitumour efficacy against the PTHrP,
by recognising the known HLA-A(*)02.01-restricted epitopes, and
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swhether the vaccination with this construct induces significant
side effects in vivo. The novel humanised mouse model used in this
study expresses HLA-A(*)02.01molecules, human b2 microglobu-
lin, and human CD8a representing an ideal model to investigate
vaccines for human utilisation. In fact, murine TCR/human MHC-
I-optimised interactions permitted us to study whether the murine
CTL response was specific for four HLA-A(*)02.01-restricted
epitopes directly onto PTH-rP-expressing human tumour cell
lines. Furthermore, sequence homology among the human and
murine PTHrP required investigation of the CTL response in the
same transgenic system as a cause of any undesired side effects or
autoimmunity signs in vivo.
MATERIALS AND METHODS
Triple knockout mice (mouse b2 microglobulin,
H-2K
b/D
b)/triple transgenic for HLA-A(*)02.01,
human b2 microglobulin, and human CD8a
Mice triple knockout (KO) (mouse b2 microglobulin, H-2K
b/D
b)/
triple transgenic for HLA-A(*)02.01, human b2 microglobulin,
and human CD8a were created at Pasteur Institut. C57BL/6
b2 microglobulin-deficient and double mutant H2-K
b/D
b mice
have already been described (Pascolo et al, 1997; Perarnau
et al, 1999). These mice were derived by sequential intercrossing
of HLA-A(*)02.01 transgenic C57BL/6 mice, human b2 micro-
globulin transgenic C57BL/6 mice, human CD8a transgenic C57BL/
6 mice, mouse b2 microglobulin KO mice, and H-2K
bD
b double
KO mice. The HLA-A(*)02.01 and human b2 microglobulin
transgenes are in genomic configuration, and the human CD8a
gene is a cDNA construct under the control of a human CD2 gene
promoter. The destruction of the mouse b2 microglobulin, mouse
H-2K
b, and D
b genes was achieved in embryonic stem cells of 129
origin. Triple transgenic/triple KO mice are homozygote for the six
genetic alterations. The genetic background of these mice is largely
from C57BL/6 origin with an undetermined proportion of 129
origin. Mice were maintained in our facilities and used for
experimentation between 6 and 8 weeks of age. All animal
experiments were carried out according to the UKCCCR Guide-
lines (Workman et al, 1998).
Cell cultures
The EL4/HHD (EL4-S3-Rob/HHD) cells are mouse b2 microglo-
bulin-deficient thymoma cells transfected with the HHD mono-
chain construct (Pascolo et al, 1997). Transient transfectants EL4/
HHD/PTH-rP (EL4-S3-Rob/HHD/PTH-rP) were obtained by
transfection of EL4-S3-Rob/HHD cells with GC90 plasmid as
previously described (Correale et al, 2001b). The prostate
carcinoma cell line LNCaP was purchased from the American
Type Culture collection (Rockville, MD, USA). Mycoplasma-free
cultures of LNCaP and EL4-S3-Rob/HHD were maintained in
complete medium (Roswell Park Modified Iscowes (RPMI)-1640,
(Life Technologies Inc. (Gibco BRL), Grand Island, NY, USA))
supplemented with 10% foetal bovine serum (FBS), 2mML -
glutamine, 100Uml
 1 penicillin, and 100mgml
 1 streptomycin
(Life Technologies, Inc.).
Peptide synthesis
Peptides PTR-1 (AVSEHQLLH), PTR-2 (FLHHLIAEIH), PTR-3
(WLDSGVTGS), and PTR-4 (TSTTSLELD) were synthesised at the
Molecular Biology Department of the University of Siena using a
solid-phase automatic peptide synthesiser (model syto, Multi-
Syntech, Witten, D) and the fluorenylmethoxycarbonyl (Fmoc)/
diisopropylcarbodiimide (DIC)/1-hydroxybenzotriazole (HOBT)
strategy. They were cleaved from the resins and defracted by
treatment with trifluoroacetic acid containing ethanedithiol, water
triisopropilsilane and anisole (93:2.5:2:1.5:1). The crude peptides
were purified by high-performance liquid chromatography (HPLC)
using a Vydac C18 column (25cm 1cm, 10mm). The products
were dissolved in double-distilled water, sterile filtered, and frozen
at  701C at a concentration of 2mgml
 1. Peptide purity was more
than 90% as analysed by HPLC. The CAP-1 peptide was kindly
provided by Dr J Schlom (EOS, NCI, Bethesda, MD, USA).
ELISpot assay
Peripheral lymphocytes isolated from blood samples collected
from the retro-orbitary sinus of the different groups of mice
were pooled and examined for PTH-rP epitope peptide-specific
precursor frequency by using the interferon-g (INF-g) ELISpot
assay (Miyahira et al, 1995). Briefly, nitrocellulose-bottomed
96-well plates (Millipore, Billerica, MA, USA) were coated for 2h
at 371C followed by overnight incubation at 41C with rat anti-
mouse IFN-g antibody (clone R4-6A2; Pharmingen). Dilutions of
responder cells in complete medium were cultured in triplicate
with or without 10mM peptide epitope for 40h. Plates were then
washed and incubated with biotinylated IFN-g antibody (clone
XMG1.2; Pharmingen, Heidelberg, Germany) followed by the
streptavidin–alkaline phosphatase conjugate (Roche Diagnostics,
Indianapolis, IN, USA). Spots were visualised using BCIP/NBT
alkaline phosphatase substrate (Promega, Madison, WI, USA).
Interferon-g-secreting cells were counted using the automated
image analysis system ELISpot Reader (AID Strassberg, Germany).
The Wilcoxon two-tail-rank test was performed to determine
whether there was a statistically significant difference between the
number of IFN-g-secreting cells in the wells stimulated with or
without the peptides of interest or with an aspecific peptide
(HIVgag76 peptide).
Generation of a PTH-rP plasmid and influenza virosomes
The PTH-rP gene was amplified from the DU-145 prostate
carcinoma cell line by means of reverse transcriptase–polymerase
chain reaction (RT–PCR) (Correale et al, 2001b) starting from
the specific mRNA by using the sense primer 50TTGGATCCA
TGCAGCGGAGACTGGTT30 and the antisense primer 50CCGAATT
CTCAATGCCTCCGTGAATCGA30, and cloned in BamHI-EcoRI
sites of the pcDNA3 expression vector (InVitrogen, Karlsruhe,
Germany) in order to obtain the recombinant plasmid GC90. The
construct was grown in DH5a cells (Life Technologies Inc.).
Plasmid DNA was purified using the Qiagen Endo Free plasmid kit
(QIAGEN, Hilden, Germany) as described by the manufacturer.
The influenza virosomes (IRIV) were prepared as described
elsewhere (Wa ˆelti and Glu ¨ck, 1998). Nonencapsulated plasmids
were separated by 0.1 gel filtration on a High Load Superdex 200
column (Amersham Pharmecia Biotech Uppsale, Sweden) equili-
brated with sterile phosphate-buffered solution (PBS). The void
volume fractions containing the virosomes and encapsulated
plasmids were eluted with PBS and collected.
Cell transfection
A total of 1.0 10
6 target cells were grown in six-well microplates
at 371C and infected with 0.3mg of DNA-virosomes or transfected
with 1mg of plasmid DNA using the Effectene Transfection reagent
(QIAGEN) as described by the manufacturer. After 2 days, PTH-rP
antigen expression was analysed by evaluating the presence of the
specific mRNA by RT–PCR and by immunofluorescence. Briefly,
the cells were washed twice with PBS, fixed with cold methanol/
acetone, and treated with a rabbit anti-PTH-rP serum (Calbio-
chem, SanDiego, USA) followed by FITC-conjugated goat anti-
rabbit IgG (1:100) (DBA, DBA s.r.l. Milan, Italy). The slides were
examined using a Diaplan microscope (Leitz, Oberkochen,
Germany).
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sImmunisation of triple KO/triple transgenic mice
Five groups of six triple KO/triple transgenic mice received 20ml
of GC90/IRIV (containing 5mg of plasmid, 0.6mg of influenza
HA, and 40ng of Escheriagen, Escherichia coli heat-labile
toxin) after intranasal (i.n.) inoculation. Mice in the
control groups received i.n. inoculation of 20ml of IRIV, or
20ml IRIV containing the plasmid backbone (pcDNA3). All groups
of mice, with the exception of those included in the control
groups, were subsequently reboosted 21 and 42 days after the
first immunisation with GC90/IRIV; PTR-1, -2, -3, and
-4 respectively. Parathyroid hormone-related protein peptides
were administered by subcutaneous (s.c.) injection at the base
of the tail with 100mg of peptide emulsified in incomplete
Freund’s adjuvant (IFA) in the presence of 140mg of the
IA
b restricted HBVcore-derived T-helper epitope (128–140;
sequence TPPAYRPPNAPIL). At 21 and 56 days after
the first immunisation, sera samples were collected from the
retro-orbital sinus for serum Ca
2þ ion level evaluation.
At 2 weeks after the final boost, the mice were killed and 4mM-
thick paraffin sections were made from sampled tissues and
stained with haematoxylin–eosin–safranin (Merck, Germany)
(Workman et al, 1998). Spleen cells (5 10
7 cells in 10ml) were
harvested on day 56 and cultured for 6 days in serum-free AIM-V
(Life Technologies Inc. (Gibco BRL)), with 2mML -glutamine,
100Uml
 1 penicillin, 100mgml
 1 streptomycin, and 100IU of
interleukin 2, and in vitro stimulated with autologous irradiated
spleen cells transfected with GC90 plasmid þ/  the cognate
peptide (10mM) used for mouse reboosting. After 6 days, the
bulk responder populations were tested for PTH-rP-specific
cytotoxicity.
Cytotoxicity assay
Target cells were labelled with 100mCi of Na2Cr
51O4 (Amersham,
Aylesbury,UK) for 60min at room temperature. Target
cells (0.5 10
4) in 100ml of complete medium (see below) were
added to each of the wells in 96-well flat-bottomed assay
plates (Corning Costar Corp., Cambridge, MA, USA). The labelled
targets were incubated at 371Ci n5 %C O 2 before the addition of
effector cells. The T cells were then suspended in 100ml of AIM-V
medium and added to the target cells. The plates were incubated at
371C for 6h, and the supernatants harvested for g-counting with
harvester frames (Skatron, Inc., Sterling, VA, USA). The determi-
nations were made in triplicate and standard deviations were
calculated. All of the experiments were repeated at least three
times.
Specific lysis was calculated as follows:
% specific lysis ¼
observed release ðc:p:m:Þ spontaneous release ðc:p:m:Þ
total release ðc:p:m:Þ spontaneous release ðc:p:m:Þ
 100
Spontaneous release was determined from the wells to which
100ml of complete medium was added instead of effector cells.
Total releasable radioactivity was obtained after treating the target
with 2.5% Triton X-100.
Blocking experiments
For HLA-blocking experiments, UPC-10 (Cappel/Organon Tech-
nique Corp., West Chester, PA, USA) control mAb or anti-HLA-A2
(A2.69, #189HA-1; One Lambda, Inc., Canoga Park, CA, USA) mAb
were added to the
51[Cr] loaded target cells (EL4/HHD/PTH-rP and
LNCaP) and incubated for 1h prior to the cytotoxic assay.
Statistical analysis
Statistical analysis of differences between means was performed
using Stat View statistical software (Abacus Concepts, Berkeley,
CA, USA). The results were expressed as the mean of four
determinations derived from two different experiments7standard
deviation. Differences among means were determined by the two-
tailed Student’s t-test for paired samples.
RESULTS
Vaccination of transgenic mice with GC90/IRIV
In order to evaluate its immunogenic potential, we administered
GC90/IRIV intranasally to five different groups of triple transgenic
mice. After 21 days, IFN-g ELISpot assays for the four HLA-
A(*)02.01 peptides PTR-1, -2, -3, and -4, were carried out on
pooled peripheral lymphocytes of all mice groups. As shown in
Table 1, a multiepitope PTH-rP peptide-specific response was
observed after a single inoculation of GC90/IRIV (Table 1). In
order to investigate the efficacy of reboost with PTH-rP peptides,
the PTH-rP-specific CTL response was then tested in the five
separate groups of GC90/IRIV-vaccinated mice that had received a
reboost with GC90/IRIV or a peptide. The first group was
reboosted with GC90/IRIV, while the other four groups were
reboosted with each one of the four PTH-rP peptides. Peripheral
lymphocytes derived from all the groups were collected 56 days
after the priming and examined by IFN-g ELISpot assays for their
Table 1 Peptide-specific CTL freshly isolated from peripheral cells of mice
a INF-g secreting cells/10
6
peripheral cells
Vaccination protocol PTH-rP peptides (1lgml
 1)
Priming Reboost PTR-1 PTR-2 PTR-3 PTR-4
GC90/IRIV
b No 1873* 1571* 2973* 1371*
IRIV
b No 471*** 571*** 572*** 471***
GC90/IRIV GC90/IRIV
c 5072* 7077* 4872* 3274*
GC90/IRIV PTR-1
c 1672**
GC90/IRIV PTR-2
c 3373*
GC90/IRIV PTR-3
c 1272**
GC90/IRIV PTR-4
c 571**
IRIV IRIV
c 472*** 872*** 1073*** 371***
CTL¼Cytotoxic T-cells; INF-g¼interferon-g; PTH-rP¼parathyroid hormone-related protein. *Po0.01 compared with
the respective intra-assay controls. **P¼0.05–0.01 compared with the respective intra-assay controls. ***P40.05
compared with the respective intra-assay controls.
aCytotoxic T-cell response was evaluated ex vivo on pooled peripheral
cells taken from the retro-orbital sinus. Specific spot numbers were obtained by subtraction of the background. Results
represent the mean of wells in triplicate.
bAt 21 days from the first immunisation.
cAt 56 days from the first immunisation.
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scapacity to recognise the four PTH-rP peptides. Results show a
multiepitope-specific CTL response in mice receiving a reboost
with GC90/IRIV, while a lower number of cognate peptide-specific
T-cell precursors frequency was detected in mice reboosted with
the single PTH-rP peptides (Table 1). The two additional groups
used as a negative control showed no response at all. Taken
together, these results suggest that GC90/IRIV is immunogenic in
vivo and that reboosting with the same construction is more
effective than with PTH-rP peptide alone to augment the number
of specific precursors in vivo.
Parathyroid hormone-related protein- specific antitumour
activity of CTL derived from GC90/IRIV-vaccinated mice
The PTH-rP-specific cytotoxicity of the CTL response was
investigated in a 6h
51Cr release assay. Spleen cells derived
from the different groups of mice vaccinated with GC90/IRIV and
reboosted with GC90/IRIV or with each one of the PTH-rP
peptides were collected and tested for their capacity to kill HLA-
A(*)02.01
þ target cells expressing PTH-rP. Controls were
represented by splenocytes derived from mice vaccinated with
the empty IRIV/pcDNA3 alone. The spleen cells derived from
the different immunisation groups were stimulated in vitro with
low-dose IL-2 and autologous irradiated spleen cells induced
to express PTH-rP protein after transfection with GC90 plasmid.
CTL cultures derived from mice vaccinated with GC90/IRIV were
able to kill murine EL4/HHD/PTH-rP target cell transfectants
(Figure 1) as well as the human HLA-A(*)02.01
þ/PTH-rP
þ
prostate carcinoma cell line LNCaP (Figure 2). Cytotoxic T-cell
cultures derived from mice primed with GC90/IRIV and boosted
with each of the four PTH-rP peptides also showed a lytic capacity
against both the targets (Figures 1 and 2), though with
a lower extent for the CTL cultures derived from mice reboosted
with PTR-1 peptide (Figures 1 and 2). Cytotoxic T-cell cultures
generated from not vaccinated control mice or from mice
vaccinated with IRIV/pcDNA3, but still in vitro stimulated
with GC90 plasmid transfected spleen cells, showed weak cytotoxic
activity against the EL4/HHD/PTH-rP transfectants (Figure 1), and
were not able to lyse the LNCaP target cell line (Figure 2). None of
the CTL cultures was able to kill murine EL4/HHD target cell lines
infected with the empty pcDNA3/IRIV vaccine as a control
(Figure 1). The lysis of murine EL4/HHD/PTH-rP transfectants
and human LNCaP target cells was HLA-A(*)02.01 restricted since
it was completely abrogated by an anti-HLA-A(*)02.01mAb
(A2.69) (Figures 1B and 2B). Conversely, the use of a negative
control mAb did not affect the target cell killing (data not shown).
These results demonstrate that vaccination of triple transgenic
mice with GC90/IRIV generated in vivo a PTH-rP-specific CTL
response able to kill tumour targets naturally processing the PTH-
rP molecule.
In vivo study after vaccination of triple transgenic mice
with GC90/IRIV
The sequence homology between the human and murine PTH-rP
protein sequences is 490%. Amino-acid homology between the
human PTR peptides and sequences of corresponding murine
PTH-rP peptides was 100% for PTR-1 and PTR-2, and 60% for
PTR-3 and PTR-4. Tissue-specific toxicity and autoimmunity
induced by GC90/IRIV vaccination was then evaluated in vivo into
transgenic mice. All vaccinated animals were killed at day 56 after
the first immunisation and analysed by histology of tissues
selected for PTH expression such as parathyroids, and PTH-rP
for skin, derma, and breast. Histology samples showed no signs of
pathologic microscopic lymphocyte infiltration of selected tissues
or any abnormal inflammation status (data not shown). These
results suggest that the GC90/IRIV vaccination generates a CTL
response specific for PTH-rP that is not able to affect the normal
tissues in vivo. Considering that the transient expression of the
whole PTH-rP protein in mice vaccinated with GC90/IRIV could
affect their physiologic Ca
2þ turnover, serum levels of Ca
2þ ions
were monitored during treatment in all mice groups (blood
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Figure 1 Parathyroid hormone-related protein-specific cytotoxic activity
of spleen cells derived from triple transgenic mice immunised with GC90/
IRIV þ/  PTH-rP peptides. Cultured spleen cells derived from different
groups of mice respectively immunised with GC90/IRIV (-K-), GC90/
IRIVþPTR-1 (-’-), GC90/IRIVþPTR-2 (-m-), GC90/IRIVþPTR-3
(-J-), GC90/IRIVþPTR-4 (-&-), and empty IRIV group (–n–).
Parathyroid hormone-related protein-specific cytotoxic activity of mouse
spleens pooled from different mouse groups was tested against EL4/HHD
target cells transfected with the PTH-rP gene (A) in fresh medium or in the
presence of anti-A2.69mAb (B).
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ssamples collected 21 and 56 days after the first inoculation of
GC90/IRIV). There was no evidence of important serum Ca
2þ ion
fluctuations in the vaccinated group (Table 2) by comparison to a
positive control group of three mice injected s.c. in the dorsal neck
with human synthetic thyrocalcitonin (0.1mg in 1ml of 0.9%
saline solution) showing a significant hypocalcaemia after 6h (0.55
of mean, Po0.03). These results indicate that GC90/IRIV is able to
elicit a PTH-rP-specific CTL response in transgenic animals
without pathologic effect on the bone osteoclastic activity or
metabolism of Ca
2þ in vivo.
DISCUSSION
In the present study we evaluated the immunological activity of
GC90/IRIV vaccine into a novel humanised mouse model triple KO
(mouse b2 microglobulin, H-2K
b/D
b)/triple transgenic (HLA-
A(*)02.01, human b2 microglobulin, human CD8a). This mouse
represents a warrant for the possibility to test immune response to
antigen-derived epitopes with amino-acid anchor motifs specific
for the human HLA-A(*)02.01 molecule. This mouse strain also
expresses the human CD8a in the form of homodimers on the T-
cell membrane for optimal interactions with the a3 domain of the
HLA-A(*)02.01 molecule. In fact, several experiments, including
crystallographic study, have documented the role of such
molecules for correct interactions with human class I HLA
molecules (Wesley et al, 1993; Sun et al, 1995; Gao et al, 1997).
In this model, such interaction allows murine CTLs to lyse tumour
cells of human origin. In addition, the absence of murine class I H-
2K
b and H-2D
b in these animals permits an efficient education of
HLA-A(*)02.01-specific CTL in the thymus as well as in the
periphery (Tanchot et al, 1997). In fact, the expression of the
human CD8molecule on murine CTL engenders an optimal TCR/
peptide/MHC trimolecular complex interaction, especially onto
human target cells, allowing the direct evaluation of the immune
response of anticancer vaccines for human purposes (Germain,
1994). Furthermore, the possibility to generate an immune
response against tumour-associated antigen (TAA) expressed by
human malignancies in such an animal model is coupled with the
opportunity to monitor the occurrence of undesirable side effects
and autoimmunity phenomena.
In this model, we found that mucosal infection with the GC90/
IRIV was able to elicit a significant multiepitopic PTH-rP-specific
CTL response with antitumour activity. This observation was of
particular interest as long as CTL precursors, stimulated by
vaccination and reboosted with GC90/IRIV, were able to recognise
the known HLA-A(*)02.01 PTH-rP epitopes (PTR-1, -2, -3, and -4)
expressed in human cancer cells. In the present study, we also
provide evidence that vaccination and reboost of transgenic mice
with the same GC90/IRIV is able to elicit a stronger multiepitopic
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Figure 2 Parathyroid hormone-related protein-specific cytotoxic activity
of spleen cells derived from triple transgenic mice immunised with GC90/
IRIV þ/  PTH-rP peptides in vitro against HLA-A(*)02.01
þ PTH-rP
þ
LNCaP cells. Cultured spleen cells were derived from different groups of
transgenic mice respectively immunised with GC90/IRIV (-K-), GC90/
IRIVþPTR-1 (-’-), GC90/IRIVþPTR-2 (-m-), GC90/IRIVþPTR-3
(-J-), GC90/IRIVþPTR-4 (-&-), and empty IRIV group (–n–).
Parathyroid hormone-related protein-specific cytotoxic activity of mouse
spleens pooled from different mouse groups was tested against LNCaP
target cells in fresh medium (A) or in the presence of anti-A2.69mAb (B).
Table 2 Serum [Ca
2+] levels in mice after vaccination with GC90/
IRIV7PTH-rP peptides
Vaccination protocol Means of three mice
Day 21 Day 56
Thyrocalcitonin
a 0.5570.02
No vaccine 1.3270.1 1.5770.03
IRIV-IRIV 1.0770.1 1.4570.005
GC90/IRIV–GC90/IRIV 1.1970.1 0.8970.2
GC90/IRIV–PTR-1 1.1870.2 1.0970.2
GC90/IRIV–PTR-2 1.0670.1 1.0070.2
GC90/IRIV–PTR-3 1.1670.2 1.1070.1
GC90/IRIV–PTR-4 1.1070.2 0.9670.1
aThe positive control was represented by a group of three mice injected s.c. in the
dorsal neck with human synthetic thyrocalcitonin (0.1mg in 1ml of 0.9% saline
solution) inducing significant hypocalcaemia values after 6h. Values of Ca
2+
concentration are given as mmoll
 17s.d.
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approach designed with synthetic peptides only. A possible
explanation could be the fact that the APC engagement and help
signals provided by the mucosal inoculation route of GC90/IRIV
construction are more effective in CD8þ response promoting
than s.c. peptide injection in IFA. In fact, previous studies revealed
that antigen encapsulated in liposomes could be successfully
delivered simultaneously into the cytosolic as well as endosomal
processing pathways of APCs, leading to the generation of both
CD4þ T helper and CD8þ cytotoxic T cells (Owais et al, 2001). It
might be useful to further investigate such aspects in order to
highlight and potentiate GC90/IRIV-mediated mechanisms of CTL
priming.
In this study, as an unexpected result we observed that the
sequential administration of PTH-rP epitope peptide after the
primary vaccination with GC90/IRIV determined a selective
reduction in the frequency of CTL precursor specific for the
cognate PTR peptide injected for re-stimulation. Three major
hypotheses were formulated in order to explain such a finding: (1)
administered peptides entering the blood circulation bind to empty
HLA-A*02.01
þ molecules on normal cells and may determine the
specific epitope peptide precursors’ lineage anergy and deletion by
HLA-A*02.01/peptide complex interaction with the specific TCR in
the absence of the correct co-accessory molecule interaction
(Perarnau et al, 1999); (2) at least three GC90/IRIV administrations
are needed to induce an effective PTH-rP-specific immune
response suggesting that the GC90/IRIV construct provides a
better helper response for CTL generation than peptides injected
with IFA adjuvant; (3) peptide administration may determine the
activation of an epitope peptide-specific CTL population that
migrates into the injection site draining lymph nodes or derma.
Our results seem to support the last hypothesis because a stronger
PTH-rP-specific cytolytic response to prostate carcinoma LNCaP
cells was observed in CTL lines derived from spleen cells taken
from mice receiving the sequential GC90/IRIV/peptide treatment.
Furthermore, peptides used for this study and derived from the
human PTH-rP sequence were chosen for their sequence homology
with the murine sequence of the same protein. Interestingly, the
PTH-rP-specific CTL response obtained after vaccination could
not engender any autoimmunity sign in vivo observed by the
histology of organs from vaccinated mice, excluding the caveat to
the cellular response against self tissues after vaccination with this
construct. This last evidence is probably due to the quality of the
CTL repertoire recruited and more likely to the low level of PTH-rP
expression in vivo in normal tissues. In fact, the endogenous PTH-
rP epitope peptide levels could be too poor to be detected by the
CTLs that are conversely able to recognise in vitro the same
antigen overexpressed on tumour cells.
Weak Ca
2þ ions reduction is present in the group of mice
immunised with GC90/IRIV, revealing mild hypocalcaemia. GC90/
IRIV vector does not let the DNA of PTHrP protein to be
integrated into the host DNA, as it happens for lentiviral or
retroviral vectors. Thus, one hypothesis is that the transient Ca
2þ
fluctuation may be due to the temporary presence of circulating
PTH-rP and this should rapidly return to normal levels with the
circulating protein disappearance. In fact, calcium ion levels are
strictly under the control of the parathyroid hormone (PTH),
which is produced by parathyroids, and shows amino-acidic
homologies with PTH-rP. Another hypothesis is that mice
vaccinated and reboosted with GC90/IRIV may produce PTH-
blocking antibodies and may determine alteration in PTH-
producing cells. Further experiments are presently in course to
investigate this hypothesis.
In conclusion, this study presents GC90/IRIV as a good vaccine
candidate to be investigated in clinical trials for human cancers
and bone metastases overexpressing PTH-rP. In addition, this is
the first description of the triple KO/triple transgenic mice that
appears to be a versatile model employed for preclinical studies of
cancer vaccines for the human HLA-A(*)02.01 haplotype back-
ground.
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